Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy
Cytotoxic chemotherapy after exposure to nivolumab (nivo), an anti-programmed death-1 (PD-1) antibody, has been associated with good response compared with historical data in various cancers including head and neck squamous cell carcinoma (HNSCC). In a previous report, different chemotherapy regimen...
Gespeichert in:
| Veröffentlicht in: | International cancer conference journal 2019-04, Vol.8 (2), p.86-88 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 88 |
|---|---|
| container_issue | 2 |
| container_start_page | 86 |
| container_title | International cancer conference journal |
| container_volume | 8 |
| creator | Koyama, Takashi Nomura, Motoo Keitaro, Doi Tateya, Ichiro Muto, Manabu |
| description | Cytotoxic chemotherapy after exposure to nivolumab (nivo), an anti-programmed death-1 (PD-1) antibody, has been associated with good response compared with historical data in various cancers including head and neck squamous cell carcinoma (HNSCC). In a previous report, different chemotherapy regimens were used before and after treatment with nivo. This HNSCC case is the first report of a good response when the same cytotoxic chemotherapy regimen was used before and after nivo. In addition, the efficacy of anti-epidermal growth factor receptor antibody after nivo treatment may be better than without exposure to nivo. |
| doi_str_mv | 10.1007/s13691-019-00360-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6498283</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2920702362</sourcerecordid><originalsourceid>FETCH-LOGICAL-c461t-b1d7306bb27768c08dec6d0d5abfd11b2017aea80e9282c25c326c8fb38fe0e63</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMoKqt_wIMUPEcnSTdNL4KsnyAooueQptPdyrapSSv23xvd9eviaTLMM--85CXkgMExA8hOAhMyZxRYTgGEBDpukF3Ock4FU2Lz13uH7IfwDAAc0hyU3CY7grE0n07TXXL9gLRue-_KwdbtPOkXmATTYGIX2LjYedONial69Am-dS4MHpPeJabta3p_TlmyZvbIVmWWAffXdUKeLi8eZ9f09u7qZnZ2S20qWU8LVmYCZFHwLJPKgirRyhLKqSmqkrGCA8sMGgWYc8Utn1rBpVVVIVSFgFJMyOlKtxuKBkuL0bxZ6s7XjfGjdqbWfydtvdBz96plmiuuRBQ4Wgt49zJg6PWzG3wbPWuec8iAC8kjxVeU9S4Ej9X3BQb6IwC9CkDHAPRnAHqMS4e_vX2vfH13BMQKCHHUztH_3P5H9h0H8pJH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2920702362</pqid></control><display><type>article</type><title>Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy</title><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>ProQuest Central</source><creator>Koyama, Takashi ; Nomura, Motoo ; Keitaro, Doi ; Tateya, Ichiro ; Muto, Manabu</creator><creatorcontrib>Koyama, Takashi ; Nomura, Motoo ; Keitaro, Doi ; Tateya, Ichiro ; Muto, Manabu</creatorcontrib><description>Cytotoxic chemotherapy after exposure to nivolumab (nivo), an anti-programmed death-1 (PD-1) antibody, has been associated with good response compared with historical data in various cancers including head and neck squamous cell carcinoma (HNSCC). In a previous report, different chemotherapy regimens were used before and after treatment with nivo. This HNSCC case is the first report of a good response when the same cytotoxic chemotherapy regimen was used before and after nivo. In addition, the efficacy of anti-epidermal growth factor receptor antibody after nivo treatment may be better than without exposure to nivo.</description><identifier>ISSN: 2192-3183</identifier><identifier>EISSN: 2192-3183</identifier><identifier>DOI: 10.1007/s13691-019-00360-y</identifier><identifier>PMID: 31149554</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Acne ; Antibodies ; Apoptosis ; Cancer therapies ; Case Report ; Chemotherapy ; Conflicts of interest ; Cytotoxicity ; Drug dosages ; Ethics ; Head & neck cancer ; Head and neck carcinoma ; Immunotherapy ; Lung cancer ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastasis ; Oncology ; Patients ; PD-1 protein ; Squamous cell carcinoma ; Surgical Oncology</subject><ispartof>International cancer conference journal, 2019-04, Vol.8 (2), p.86-88</ispartof><rights>The Japan Society of Clinical Oncology 2019</rights><rights>The Japan Society of Clinical Oncology 2019.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c461t-b1d7306bb27768c08dec6d0d5abfd11b2017aea80e9282c25c326c8fb38fe0e63</citedby><cites>FETCH-LOGICAL-c461t-b1d7306bb27768c08dec6d0d5abfd11b2017aea80e9282c25c326c8fb38fe0e63</cites><orcidid>0000-0002-5967-0610</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498283/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2920702362?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,21367,27901,27902,33721,41464,42533,43781,51294,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31149554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koyama, Takashi</creatorcontrib><creatorcontrib>Nomura, Motoo</creatorcontrib><creatorcontrib>Keitaro, Doi</creatorcontrib><creatorcontrib>Tateya, Ichiro</creatorcontrib><creatorcontrib>Muto, Manabu</creatorcontrib><title>Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy</title><title>International cancer conference journal</title><addtitle>Int Canc Conf J</addtitle><addtitle>Int Cancer Conf J</addtitle><description>Cytotoxic chemotherapy after exposure to nivolumab (nivo), an anti-programmed death-1 (PD-1) antibody, has been associated with good response compared with historical data in various cancers including head and neck squamous cell carcinoma (HNSCC). In a previous report, different chemotherapy regimens were used before and after treatment with nivo. This HNSCC case is the first report of a good response when the same cytotoxic chemotherapy regimen was used before and after nivo. In addition, the efficacy of anti-epidermal growth factor receptor antibody after nivo treatment may be better than without exposure to nivo.</description><subject>Acne</subject><subject>Antibodies</subject><subject>Apoptosis</subject><subject>Cancer therapies</subject><subject>Case Report</subject><subject>Chemotherapy</subject><subject>Conflicts of interest</subject><subject>Cytotoxicity</subject><subject>Drug dosages</subject><subject>Ethics</subject><subject>Head & neck cancer</subject><subject>Head and neck carcinoma</subject><subject>Immunotherapy</subject><subject>Lung cancer</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Oncology</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Squamous cell carcinoma</subject><subject>Surgical Oncology</subject><issn>2192-3183</issn><issn>2192-3183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNp9kU1LxDAQhoMoKqt_wIMUPEcnSTdNL4KsnyAooueQptPdyrapSSv23xvd9eviaTLMM--85CXkgMExA8hOAhMyZxRYTgGEBDpukF3Ock4FU2Lz13uH7IfwDAAc0hyU3CY7grE0n07TXXL9gLRue-_KwdbtPOkXmATTYGIX2LjYedONial69Am-dS4MHpPeJabta3p_TlmyZvbIVmWWAffXdUKeLi8eZ9f09u7qZnZ2S20qWU8LVmYCZFHwLJPKgirRyhLKqSmqkrGCA8sMGgWYc8Utn1rBpVVVIVSFgFJMyOlKtxuKBkuL0bxZ6s7XjfGjdqbWfydtvdBz96plmiuuRBQ4Wgt49zJg6PWzG3wbPWuec8iAC8kjxVeU9S4Ej9X3BQb6IwC9CkDHAPRnAHqMS4e_vX2vfH13BMQKCHHUztH_3P5H9h0H8pJH</recordid><startdate>20190401</startdate><enddate>20190401</enddate><creator>Koyama, Takashi</creator><creator>Nomura, Motoo</creator><creator>Keitaro, Doi</creator><creator>Tateya, Ichiro</creator><creator>Muto, Manabu</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5967-0610</orcidid></search><sort><creationdate>20190401</creationdate><title>Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy</title><author>Koyama, Takashi ; Nomura, Motoo ; Keitaro, Doi ; Tateya, Ichiro ; Muto, Manabu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c461t-b1d7306bb27768c08dec6d0d5abfd11b2017aea80e9282c25c326c8fb38fe0e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acne</topic><topic>Antibodies</topic><topic>Apoptosis</topic><topic>Cancer therapies</topic><topic>Case Report</topic><topic>Chemotherapy</topic><topic>Conflicts of interest</topic><topic>Cytotoxicity</topic><topic>Drug dosages</topic><topic>Ethics</topic><topic>Head & neck cancer</topic><topic>Head and neck carcinoma</topic><topic>Immunotherapy</topic><topic>Lung cancer</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Oncology</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Squamous cell carcinoma</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koyama, Takashi</creatorcontrib><creatorcontrib>Nomura, Motoo</creatorcontrib><creatorcontrib>Keitaro, Doi</creatorcontrib><creatorcontrib>Tateya, Ichiro</creatorcontrib><creatorcontrib>Muto, Manabu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International cancer conference journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koyama, Takashi</au><au>Nomura, Motoo</au><au>Keitaro, Doi</au><au>Tateya, Ichiro</au><au>Muto, Manabu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy</atitle><jtitle>International cancer conference journal</jtitle><stitle>Int Canc Conf J</stitle><addtitle>Int Cancer Conf J</addtitle><date>2019-04-01</date><risdate>2019</risdate><volume>8</volume><issue>2</issue><spage>86</spage><epage>88</epage><pages>86-88</pages><issn>2192-3183</issn><eissn>2192-3183</eissn><abstract>Cytotoxic chemotherapy after exposure to nivolumab (nivo), an anti-programmed death-1 (PD-1) antibody, has been associated with good response compared with historical data in various cancers including head and neck squamous cell carcinoma (HNSCC). In a previous report, different chemotherapy regimens were used before and after treatment with nivo. This HNSCC case is the first report of a good response when the same cytotoxic chemotherapy regimen was used before and after nivo. In addition, the efficacy of anti-epidermal growth factor receptor antibody after nivo treatment may be better than without exposure to nivo.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31149554</pmid><doi>10.1007/s13691-019-00360-y</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-5967-0610</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2192-3183 |
| ispartof | International cancer conference journal, 2019-04, Vol.8 (2), p.86-88 |
| issn | 2192-3183 2192-3183 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6498283 |
| source | SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; ProQuest Central |
| subjects | Acne Antibodies Apoptosis Cancer therapies Case Report Chemotherapy Conflicts of interest Cytotoxicity Drug dosages Ethics Head & neck cancer Head and neck carcinoma Immunotherapy Lung cancer Medical prognosis Medicine Medicine & Public Health Metastasis Oncology Patients PD-1 protein Squamous cell carcinoma Surgical Oncology |
| title | Re-introducing the same chemotherapy after exposure to anti-PD-1 therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T03%3A14%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Re-introducing%20the%20same%20chemotherapy%20after%20exposure%20to%20anti-PD-1%20therapy&rft.jtitle=International%20cancer%20conference%20journal&rft.au=Koyama,%20Takashi&rft.date=2019-04-01&rft.volume=8&rft.issue=2&rft.spage=86&rft.epage=88&rft.pages=86-88&rft.issn=2192-3183&rft.eissn=2192-3183&rft_id=info:doi/10.1007/s13691-019-00360-y&rft_dat=%3Cproquest_pubme%3E2920702362%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2920702362&rft_id=info:pmid/31149554&rfr_iscdi=true |